Mechanisms of resistance in castration-resistant prostate cancer (CRPC) - sprookjes - yvandenbroek - TriplyDB

Mechanisms of resistance in castration-resistant prostate cancer (CRPC)

Mechanisms of resistance in castration-resistant prostate cancer (CRPC)

http://www.wikidata.org/entity/Q26774221

about

Oncolytic adenovirus-mediated therapy for prostate cancer Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer The role of prostate tumor overexpressed 1 in cancer progression Epigenomic Regulation of Androgen Receptor Signaling: Potential Role in Prostate Cancer Therapy.Novel Nine-Exon AR Transcripts (Exon 1/Exon 1b/Exons 2-8) in Normal and Cancerous Breast and Prostate Cells.Androgen Receptor Regulates the Growth of Neuroblastoma Cells in vitro and in vivo Proteasome-associated deubiquitinase ubiquitin-specific protease 14 regulates prostate cancer proliferation by deubiquitinating and stabilizing androgen receptor.Heat shock protein 70 inhibitors suppress androgen receptor expression in LNCaP95 prostate cancer cells.TGF-β Effects on Prostate Cancer Cell Migration and Invasion Require FosB.Analysis of STAT3 post-translational modifications (PTMs) in human prostate cancer with different Gleason Score.Phosphorylation-induced conformational dynamics in an intrinsically disordered protein and potential role in phenotypic heterogeneity.Niclosamide: Beyond an antihelminthic drug.AR Signaling and the PI3K Pathway in Prostate Cancer Successful Yttrium-90 Microsphere Radioembolization for Hepatic Metastases of Prostate Cancer.Prostate Tumor Overexpressed-1 (PTOV1) promotes docetaxel-resistance and survival of castration resistant prostate cancer cells.Comparing the clinical efficacy of abiraterone acetate, enzalutamide, and orteronel in patients with metastatic castration-resistant prostate cancer by performing a network meta-analysis of eight randomized controlled trials.ABCB1 Mediates Cabazitaxel-Docetaxel Cross-Resistance in Advanced Prostate Cancer.Intermediate PSA half-life after neoadjuvant hormone therapy predicts reduced risk of castration-resistant prostate cancer development after radical prostatectomy.Genomic Activation of PPARG Reveals a Candidate Therapeutic Axis in Bladder Cancer.Identification of genes associated with castration‑resistant prostate cancer by gene expression profile analysis.Pharmacological treatment with inhibitors of nuclear export enhances the antitumor activity of docetaxel in human prostate cancer.Activation of p53 and destabilization of androgen receptor by combinatorial inhibition of MDM2 and MDMX in prostate cancer cells.ATM‑JAK‑PD‑L1 signaling pathway inhibition decreases EMT and metastasis of androgen‑independent prostate cancer.Traditional Chinese Medicine CFF-1 induced cell growth inhibition, autophagy, and apoptosis via inhibiting EGFR-related pathways in prostate cancer.Plk1 inhibition enhances the efficacy of BET epigenetic reader blockade in castration-resistant prostate cancer.Integrative (epi) Genomic Analysis to Predict Response to Androgen-Deprivation Therapy in Prostate Cancer.Frizzled-8 integrates Wnt-11 and transforming growth factor-β signaling in prostate cancer.Design of Peptoid-peptide Macrocycles to Inhibit the β-catenin TCF Interaction in Prostate Cancer Linking cellular metabolism and metabolomics to risk-stratification of prostate cancer clinical aggressiveness and potential therapeutic pathways Chronic hypoxia-induced slug promotes invasive behavior of prostate cancer cells by activating expression of ephrin-B1 Mutant allele quantification reveals a genetic basis for TP53 mutation-driven castration resistance in prostate cancer cells Improving adenoviral vectors and strategies for prostate cancer gene therapy

P2860

Q27004796-AD007289-B66B-444F-8F89-286EA1D04F7F Q28075965-BE045829-700D-4A3E-B4E5-50470A3B4484 Q28079350-DC5AB382-475F-46F0-AEB6-A5708E17B23D Q37629548-37087328-C482-4646-A737-D961239DA61E Q37631437-521D8B40-FEB4-4871-ADC4-0519D473117A Q37683259-C24BC5D3-3726-4641-AE1D-3F0016130319 Q37745139-20A69D8E-F60D-49A3-879A-6962DF629570 Q38697766-AC155CC9-E2DB-4A3A-96B8-FA028E023AEC Q38747679-CBA2D537-55CC-4AFD-BC13-7E4CF288A777 Q38794210-C3406A3D-9CAB-40A2-941C-530A9FE70974 Q38910392-A8EAFABB-CEBE-4403-ABE8-43C77E7A6029 Q39227540-6C384FF2-146B-4121-B58E-72878632BCAD Q39249001-1D7796BC-E212-47A8-A003-BBE160CECB7E Q41485921-9FE4D763-06DA-4936-B23F-7DEF8FA948E0 Q41708911-F68D23CB-9B9D-4724-9BCA-77CF2DBDA7E2 Q41709181-56A89A9E-E8C8-42C2-A70D-CF5BD4B86090 Q46495734-045EDF58-4A57-404D-9296-D858B336DBF3 Q47114438-44E1347C-50B8-447E-B5D9-DC7AA70581D4 Q47782346-2F75750C-2CCF-459B-AC93-A6846BCAB718 Q47811759-B7504740-37C0-4455-8356-FE7EC8849382 Q49164320-E07BCF0A-AACE-4ACB-BDBF-FFE5B76413CD Q49787526-61A12F8E-BAC2-4CCB-BA53-6497EBA07267 Q52641296-E67957DE-DEEF-4913-87C3-7E26A1C10AEF Q52658477-50C7133A-81F3-46AA-8115-A20541EA5E0B Q52714957-86A3D5E5-5754-4C3B-BA00-62483AC661D0 Q53692348-01202C27-7405-4547-94BB-B21E621A2D7A Q55519861-C3EF14DD-5F1F-4487-B195-96B7D93A899B Q57798889-33E1D257-4EF9-40C4-BA19-959778743088 Q58562101-A12A4C5A-B325-46C9-B778-D02AD81EF2A4 Q58692417-AA1E2C10-FF38-4F6B-8C86-E82C19439E16 Q58731111-B79F87C5-BA85-4B9B-A7D8-8B194A1544F5 Q58801177-2BC33880-CA1D-4761-8649-15A8C2FB70C2

P2860

Mechanisms of resistance in castration-resistant prostate cancer (CRPC)

http://www.wikidata.org/entity/Q26774221

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Mechanisms of resistance in castration-resistant prostate cancer (CRPC)

@ast

Mechanisms of resistance in castration-resistant prostate cancer (CRPC)

@en

Mechanisms of resistance in castration-resistant prostate cancer (CRPC)

@nl

type

label

Mechanisms of resistance in castration-resistant prostate cancer (CRPC)

@ast

Mechanisms of resistance in castration-resistant prostate cancer (CRPC)

@en

Mechanisms of resistance in castration-resistant prostate cancer (CRPC)

@nl

prefLabel

Mechanisms of resistance in castration-resistant prostate cancer (CRPC)

@ast

Mechanisms of resistance in castration-resistant prostate cancer (CRPC)

@en

Mechanisms of resistance in castration-resistant prostate cancer (CRPC)

@nl

P1433

Q26774221-01A01CF1-35D8-4E5E-9B40-E7CF8D1848B2

P1476

Q26774221-E1244E75-221D-4B10-AD13-5A0433DB5DB2

P2093

Q26774221-A9B2D3F3-D759-4117-B696-67C2346596F9

Q26774221-BB4E9A42-7995-44F4-95F0-D8CD22BFC8A8

Q26774221-ECCF5910-54C4-476C-BB25-B88558CF3FDA

P2860

Q26774221-000BC99A-1220-4514-A9F1-F939C994DD0E

Q26774221-02D87DFE-8214-4F41-A40A-A74EC545E4E8

Q26774221-04799336-861A-4EF0-8C40-457D68A586A8

Q26774221-064953AD-8605-4F2C-BEAC-E2A4C65C45BF

Q26774221-070F3767-D5A5-4A88-81D5-5342D2422282

Q26774221-07328B8F-9779-4244-993A-7F809ED2F18F

Q26774221-08C05A76-D358-45D9-B5C9-090D9D994320

Q26774221-0911B237-BA06-44DC-A158-1729F7782B1B

Q26774221-0A5DF432-7A34-4B61-914E-6A5FA4693965

Q26774221-0A68DCBB-E043-4890-BBBD-DEF4521C4D44

P304

Q26774221-21C575FB-0588-4508-860D-847FE06EDDDC

P31

Q26774221-F77C753B-F7E0-4561-900A-3D507E7121C7

P3181

Q26774221-BF67CFFF-0E51-4AA5-8C49-66046FA0557A

P356

Q26774221-ED0EA914-3CE3-436E-847B-64A373C275CD

P407

Q26774221-160F4371-1A07-42AA-B5A8-804CB278C12A

P433

Q26774221-A9B1AB55-5C1F-4A84-83A9-F9126FF748D2

P478

Q26774221-899D6AB7-479F-4BFF-B77F-A6DC2659A1C9

P50

Q26774221-5246A261-F2EF-454B-8F7F-ADD75F859F94

P577

Q26774221-E58C9855-3EB5-4848-BD4D-5DDD07CA92FB

P698

Q26774221-F93AE30D-62D4-4C0D-ADD3-2B4138615B19

P932

Q26774221-90017774-94AE-4CCC-8F48-2980AD6B8D74

P3181

P356

J.ISSN.2223-4683.2015.05.02

P1433

Translational andrology and urology

P1476

Mechanisms of resistance in castration-resistant prostate cancer (CRPC)

@en

P2093

Allen C Gao

http://www.w3.org/2001/XMLSchema#string

Christopher P Evans

http://www.w3.org/2001/XMLSchema#string

Joy C Yang

http://www.w3.org/2001/XMLSchema#string

P2860

Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival

Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression

An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression

Clusterin inhibits apoptosis by interacting with activated Bax

Abiraterone in metastatic prostate cancer without previous chemotherapy

Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase

Androgen insensitivity syndrome

Abiraterone in the treatment of metastatic castration-resistant prostate cancer

Autophagy: a targetable linchpin of cancer cell metabolism

SRC: marker or actor in prostate cancer aggressiveness

P304

365-380

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3074510

http://www.w3.org/2001/XMLSchema#string

P356

10.3978/J.ISSN.2223-4683.2015.05.02

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Thenappan Chandrasekar

P577

2015-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26814148

http://www.w3.org/2001/XMLSchema#string

P932

4708226

http://www.w3.org/2001/XMLSchema#string